BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20927588)

  • 1. Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.
    Wu S; Fukai K; Imazeki F; Arai M; Kanda T; Yonemitsu Y; Yokosuka O
    Dig Dis Sci; 2011 Apr; 56(4):1207-14. PubMed ID: 20927588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
    J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of initial virologic response to adefovir on the development of resistance to adefovir in lamivudine-resistant chronic hepatitis B].
    Kim IH; Kim SH; Kim HC; Shin KD; Kim SW; Lee SO; Lee ST; Kim DG
    Korean J Hepatol; 2007 Sep; 13(3):349-62. PubMed ID: 17898551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
    Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
    Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
    J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir.
    Lee JM; Kim HJ; Park JY; Lee CK; Kim DY; Kim JK; Lee HW; Paik YH; Lee KS; Han KH; Chon CY; Hong SP; Nguyen T; Ahn SH
    Antivir Ther; 2009; 14(5):705-12. PubMed ID: 19704174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
    Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
    World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
    Lai HW; Chang CC; Chen TH; Tsai MC; Chen TY; Lin CC
    J Formos Med Assoc; 2012 Aug; 111(8):439-44. PubMed ID: 22939662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.
    Kurashige N; Hiramatsu N; Ohkawa K; Yakushijin T; Kiso S; Kanto T; Takehara T; Kasahara A; Doi Y; Yamada A; Oshita M; Mita E; Hagiwara H; Nagase T; Yoshihara H; Hayashi E; Imai Y; Kato M; Kashihara T; Hayashi N
    J Gastroenterol; 2009; 44(6):601-7. PubMed ID: 19387534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.